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Edited by Gianni CesareniAbstract Antimicrobial peptides and proteins are key eﬀectors
of innate immunity, expressed both by circulating phagocytic
cells and by epithelial cells of mucosal tissues. In the human
small intestine, Paneth cells are secretory epithelial cells that ex-
press the antimicrobials human a-defensin-5 (HD5), HD6, lyso-
zyme and secretory phospholipase A2 (sPLA2), and recent
studies have implicated reduced HD5 and HD6 expression levels
in the pathogenesis of ileal Crohn’s disease. However, expression
levels of these molecules have not been determined routinely by
techniques that readily permit quantitative comparisons of their
distribution between tissues and samples. Using quantitative
real-time PCR with external standards and Northern blot anal-
ysis, we compared expression levels of mRNA encoding these
four Paneth cell antimicrobial peptides, as well as circulating hu-
man neutrophil defensins in several diﬀerent gastrointestinal tis-
sues and the bone marrow. HD5 and HD6 were the most
abundant antimicrobials expressed in the small intestine. The
concentration of HD5 mRNA is approximately 5 · 105 copies
per 10 ng RNA in the jejunum and ileum; HD6 mRNA levels
were about six times lower than those of HD5. With the excep-
tion of low levels in the pancreas (103 copies/10 ng RNA), the
expression of HD5 and HD6 in tissues other than small intestine
was at or below detectable limits. The expression of sPLA2 and
lysozyme mRNA was observed in the small intestine (approxi-
mately, 3 · 103 and 9 · 103 copies/10 ng RNA, respectively),
but also in several other tissues. Lysozyme expression was high
in the duodenum (105 copies/10 ng RNA), and the protein local-
ized to both Brunner’s glands in the lamina propria and Paneth
cells. By comparison, the hematopoietic a-defensins HNP1-3
mRNA were detected at 6 · 105 copies per 10 ng RNA in the
bone marrow. These quantitative RT-PCR data from healthy tis-
sues represents the ﬁrst quantitative topographical assessment of
antimicrobial expression in the gastrointestinal tract and pro-
vides a means to directly compare expression levels between
healthy tissues and disease specimens for multiple antimicrobial
peptides.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Antimicrobial peptides and proteins are key eﬀector mole-
cules of innate immunity [1–5]. Their abundant expression in
circulating phagocytic cells provides these cells a mechanism
to kill infectious microbes that have penetrated host tissues.
Many of the same eﬀector molecules are also expressed by epi-
thelial cells, where they contribute to the defense of mucosal
surfaces [6–9]. The use of similar or identical antimicrobial
eﬀector molecules by both phagocytic cells and mucosal epi-
thelial cells is a phenomenon observed throughout the animal
kingdom [2]. Human examples of this duality of expression in-
clude the antimicrobial peptides defensins and cathelicidin
LL-37, the enzymes lysozyme and sPLA2, and the iron-seques-
tering proteins lipocalin-2 and lactoferrin.
In terms of host defense, the small intestinal mucosa is a
remarkable epithelial surface [10,11]. The expansive surface
epithelium, required for adequate nutrient absorption, is a
potential site for microbial invasion. This surface epithelium
undergoes continual cellular renewal, and the stem cells that
replenish this surface epithelium require continuous antimicro-
bial protection since breaches in the epithelial barrier could
result from damage to these progenitor cells. Together, these
observations highlight that very eﬀective mucosal host defense
mechanisms are present in the small intestine [11,12].
Paneth cells are secretory epithelial cells that reside at the
base of the small intestinal crypts, in close proximity to the
aforementioned stem cells, and these cells express a collection
of antimicrobial substances, stored in large cytoplasmic gran-
ules and released into the crypt lumen [13]. In vivo studies using
murine models have provided strong support for the proposed
protective functions of Paneth cell antimicrobials against en-
teric pathogens [14,15]. Human Paneth cells express a-defen-
sins, lysozyme and sPLA2 [13]. Recent data has linked
reduced Paneth cell defensin expression with susceptibility to
the chronic inﬂammation of ileal Crohn’s disease [16,17]. In
addition to the molecules expressed in humans, rodent Paneth
cells also express other antimicrobials [18,19]. All of these
eﬀector molecules are proposed to contribute to innate im-
mune defenses in the small intestine, and the implicit hypoth-
esis is that variation in the regional expression of these
antimicrobials in the gastrointestinal tract reﬂects diﬀerent
dynamics of host–microbe interactions along this mucosal sur-
face. However, expression levels of these molecules have not
been determined by techniques that readily permit quantitativeblished by Elsevier B.V. All rights reserved.
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sented here provides such a quantitative analysis of the mRNA
encoding antimicrobials of human Paneth cells. Using quanti-
tative real-time PCR with external standards, we examine the
levels of expression in the small intestine and other gastrointes-
tinal tissues, comparing these levels to those of hematopoietic
cells in the bone marrow.2. Methods
2.1. Tissue
Redundant, surgically resected small intestinal specimens were ob-
tained from individuals undergoing surgery for cancer, bowel obstruc-
tion, or some other non-inﬂammatory condition. Tissue samples were
provided by the Cooperative Human Tissue Network, which is funded
by the National Cancer Institute. Other investigators may have re-
ceived specimens from the same subjects. An institutional review board
approved the protocols. Specimens were processed for routine histo-
logical evaluation and tissue samples used for RNA isolation were free
of macroscopic and microscopic signs of disease or inﬂammation.
Prior to RNA isolation, samples were frozen in liquid nitrogen and
stored at 80 C. Commercial sources of RNA (Clontech BD Biosci-
ences, Palo Alto, CA and Ambion, Inc. Austin, TX) were obtained
from adult cadaver tissues.
2.2. Ribonucleic acid isolation and reverse transcription
Frozen small intestinal specimens were disrupted mechanically, and
total RNA was isolated using cesium chloride gradient ultracentrifuga-
tion as described [20]. Alternatively, total RNA from other tissues was
obtained from commercial sources. RNA integrity was assessed using
agarose gel electrophoresis and ethidium bromide staining, and then
quantitated in duplicate using ultraviolet absorption spectrometry at
260 nm. The RNA was then used for either Northern blot analysis
or reverse transcription cDNA synthesis. For cDNA synthesis, 5 lg
of total RNA was reverse transcribed with Superscript II reverse trans-
criptase (50 U) using an oligo- (dT)12–18 primer according to the sup-
plier’s protocol (Invitrogen, Carlsbad, CA). The single-stranded
cDNA product was puriﬁed using column adsorption chromatography
(Qiagen, Valencia, CA). A single cDNA preparation from each speci-
men was used for the assay of all antimicrobial products tested. Con-
trol experiments using RNA isolated from a single specimen to
synthesize, isolate and purify the cDNA showed reaction-to-reaction
variability was 615%.
2.3. Northern blot analysis
RNA was size-fractionated by agarose gel electrophoresis in the
presence of formaldehyde and blotted to nylon membranes (Hybond-
N, Amersham) by the capillary technique [21]. The oligonucleo-
tide hybridization probes were as follows: HD5 (HSIA-309a,
TGCTTTGGTTTCTATCTAGGAAGCTCAGCGACAGCAGAGT-
CTGTAGAG), HD6 (HSIB-309a TCATCCCTCAGAGGCA-
GCAGAATCTGTGGTTAATACCCATGACAGTGC), lysozyme
(hLys-1a, TGCACAAGCTACAGCATCAGCGATGTTATCTTG-
CAGC), sPLA2 (hsPLA2-1a, GAGGGTCTTCATGGTAAGAGTT-
CTTGGGTGACAAATG). A glyceraldehyde-3-phosphate dehydro-
genase probe (GAPDH-1a, AGCCCCRGCCTTCTCCATGGTRGT-
GAAAGACVVCCR) was used to assess RNA levels and integrity.
Probes were end-labeled with c-[32P] ATP and polynucleotide kinase
as described [22]. Labeled probes were incubated overnight withTable 1
Oligonucleotide sequences used in real-time RT-PCR analysis
Sense
HD5 50-GCCATCCTTGCTGCCATT-30
HD6 50-CCACTCCAAGCTGAGGAT-30
sPLA2 50-CGCACTCAGTTATGGCTTCTACG-3
Lysozyme 50-AAAACCCCAGGAGCAGTTAAT-30
HNP1-3 50-GCGGACATCCCAGAAGTGGTTG-30
GAPDH 50-CCAGCCGAGCCACATCGCTC-3 0Northern blot membranes in 35% (v/v) formamide, 5· SSC, 5% Den-
hardt’s solution and 1% (w/v) SDS at 42 C, and then washed at high
stringency in 2· SSC and 0.1% SDS at 55 C for 30 min. The mem-
branes were then exposed to photographic ﬁlm with an intensifying
screen at 80 C. Signal intensity of Northern blots was quantiﬁed
using Phosphorimager analysis (Molecular Dynamics, Sunnyvale
CA). The quantitated signal for a-defensin mRNA on Northern blots
was normalized using the GAPDH mRNA signal of each sample.
After each analysis, the probes were stripped from the membrane by
incubation in 0.1· SSC and 0.1% SDS at 70 C for 30 min, and ex-
posed to ﬁlm to ensure complete probe removal before hybridization
with another probe. The duodenal specimen was similarly analyzed
as described [23].
2.4. Cloning of gene speciﬁc plasmids
The cDNAs encoding HD5, HD6, HNP-1, sPLA2, lysozyme, and
GAPDH were cloned into a Bluescript plasmid vector (Stratagene,
La Jolla, CA) according to standard procedures [24,25]. Plasmids were
sequenced to conﬁrm identity using dideoxynucleotide methodology.
These gene speciﬁc plasmids were then quantitated (by both spectro-
photometric absorbance at 260 nm and ethidium bromide staining aga-
rose electrophoresis gels with DNA standards), serially diluted in yeast
RNA (0.2 lg/ll) as a carrier nucleic acid, and then used in real-time
PCR to generate standard curves for each reaction.2.5. Real-time PCR
Real-time PCR was performed using single-stranded cDNA from
tissue (or gene-speciﬁc plasmids as controls) with speciﬁc oligonucleo-
tide primer pairs (Table 1) in a temperature cycler equipped with a
ﬂuorescence detection monitor (LightCycler, Roche Diagnostics,
Mannheim, Germany) as described previously [17,26,27]. Brieﬂy,
cDNA corresponding to 10 ng RNA served as a template in a 10 ll
reaction containing 4 mMMgCl2, 0.5 lM of each primer and 1· Light-
Cycler-Fast Start DNA Master SYBR Green I mix (Roche Diagnos-
tics). This technique continually monitors the cycle-by-cycle
accumulation of ﬂuorescence signal from intercalation of the SYBR
green probe into the PCR product. A negative control reaction that
omitted template cDNA was included with each set of reactions to
check for possible cross-contamination. The PCR conditions were: ini-
tial denaturation at 95 C for 10 min, followed by 45 cycles with each
cycle consisting of denaturation, 95 C for 15 s; annealing at 60 C for
5 s; and extension at 72 C for 10 s. The cycle-to-cycle ﬂuorescence
emission was monitored at 530 nm and analyzed using LightCycler
Software (Roche Diagnostics). Gene-speciﬁc plasmid standards were
included with every set of reactions.
PCR primers (Table 1) were selected using Mac Vector 7.2 software
(Accelrys, Inc., San Diego, CA) and purchased from Biosource (Cam-
arillo, CA). The eﬃciency of PCR ampliﬁcation (E = 101/slope, where
the slope refers to the slope of the standard curve expressed as crossing
point (PCR cycle where ﬂuorescence rises above background) vs. log of
the template DNA concentration) was analyzed using LightCycler soft-
ware, and all primer pairs had an eﬃciency coeﬃcient of 1.9 or higher.
To conﬁrm PCR ampliﬁcation of the intended product, a represen-
tative sample from all six reactions was analyzed by electrophoresis on
a 2% agarose gel. The products were visualized by ethidium bromide
staining and compared to DNA size standards to conﬁrm anticipated
product size. In addition, a second representative sample was analyzed
by direct DNA sequence determination. In addition, melting tempera-
ture proﬁle curves of every PCR reaction was determined at the end of
each reaction by cooling the sample to 65 C for 15 s and then heating
slowly at 0.20 C/s with continuous measurement of ﬂuorescence until
a temperature of 95 C was reached. A change in ﬂuorescent intensityAntisense
50-GCTTCTGGGTTGTAGCCTCATC-3 0
50-CTCTGCAAAGGAGACGGC-30
0 50-AGGTGATTCTGCTCCCCGAG-30
50-CAACCCTCTTTGCACAAGCT-30
50-TCAGCAGCAGAATGCCCAGAGTC-30
50-ATGAGCCCCAGCCTTCTCCAT-30
Fig. 1. Northern blot analysis of antimicrobial peptide expression in
the GI tract. RNA from adult, human, non-diseased intestinal tissues
was analyzed using probes for HD5, HD6, lysozyme, sPLA2 and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Duodenal
sample was from a commercial source as described [23]. The
autoradiographic exposure was 2 days (left panels) and 3 days (right
panels).
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ture where the rate of observed change is the greatest is deﬁned as
the melting point. Because the melting temperature of the double
stranded DNA is dependent on length, relative GC content, and se-
quence, PCR products can often be distinguished by their melting
point.
Control experiments were performed to assess the reproducibility of
the various steps of the quantitative analysis. For assessment of intra-
sample reproducibility, RNA from ﬁve diﬀerent specimens was used to
synthesize, isolate and purify cDNA templates in quadruplicate, as de-
scribed above. Real-time PCR on these twenty samples was performed
to determine HD5 levels, and the standard deviation relative to the
mean for each of the ﬁve samples was 0.09, 0.09, 0.13, 0.20 and 0.32.
From other reactions, the variability observed for individual samples
assayed in separate reactions on diﬀerent days was approximately
10%. The variability observed for replicates of samples within a single
reaction was also approximately 10%.
2.6. Immunohistochemistry and immunoﬂuorescence
Freshly obtained pancreatic or duodenal tissue was ﬁxed in 10%
neutral buﬀered formalin before paraﬃn embedding. The tissue pro-
cessing and methods for immunohistochemistry were as described
[28,29]. Brieﬂy, sections were deparaﬃnated, hydrated in a graded ser-
ies of alcohols, treated with peroxide and washed in PBS pH 7.4. The
sections were blocked with 5% normal goat serum, and then incubated
in the rabbit polyclonal HD5 antiserum [30] for 20 h at 4 C in a
humidiﬁed chamber. Sections were then washed in PBS, blocked with
goat serum, followed by incubation with biotinylated goat anti-rabbit
(1:200; Vector Laboratories, Inc., Burlingame, CA) for 20 min at room
temperature. 5% normal goat serum was used as diluent for antisera.
The sections were then treated with avidin–biotin complex, incubated
with DAB substrate for 5 min at room temperature, followed by light
green counterstain.
For immunoﬂuorescence, the duodenal tissue section was blocked
with 0.15% horse serum in PBS for 20 min. Anti-HD5 monoclonal
antibody (8c8, 1:6000) [23] and rabbit polyclonal anti-lysozyme anti-
serum (1:3000) (Dako, Carpinteria, CA) were used as primary antibod-
ies and were incubated overnight at 4 C. The tissue sections were then
washed in PBS and treated with Alexa Fluor 488-conjugated anti-rab-
bit (Molecular Probes, Eugene, OR), and biotin-anti-mouse (Vector
Laboratories) followed by Alexa Fluor 568-streptavidin (Molecular
Probes-Invitrogen, Carlsbad, CA). Sections were mounted with Vecta-
shield with DAPI (Vector Laboratories) and the edges of the coverslips
were sealed with clear nail polish. Confocal images were obtained as
described [29].3. Results
3.1. Northern blot analysis
There are four known antimicrobial polypeptides expressed
in human Paneth cells: HD5, HD6, lysozyme and sPLA2 [13].
Northern analysis was used to identify the tissue expression
pattern of these Paneth cell antimicrobials in the human intes-
tine. The results (Fig. 1) indicate that HD5 and HD6 are ex-
pressed in duodenum, jejunum and ileum, but not the colon,
consistent with previous studies [23,24,31]. Quantitation of
the relative amounts of signal using phosphorimager analysis
indicates that there is approximately four times more HD5
than HD6 mRNA in the jejunum and six times more HD5
in the ileum (data not shown). In contrast to this expression
pattern, lysozyme and sPLA2 mRNA were observed in colon
and small intestine, with the level of lysozyme mRNA in the
colon near the lower limits of detection. Interestingly, lyso-
zyme mRNA levels were high in the duodenum (Fig. 1).
3.2. Quantitative real time RT-PCR analysis
Standard curves were determined for each real-time PCR
reaction using oligonucleotide primers as shown in Table 1.
For example, a full-length lysozyme cDNA was cloned fromintestinal cDNA and conﬁrmed by sequence analysis. The
plasmid containing this cDNA was quantiﬁed, serially diluted,
and used as a PCR template in real-time RT-PCR (Fig. 2A) to
generate a standard curve (Fig. 2A inset). The standard curve
spans concentrations equivalent to 5.5 · 108–5.5 · 101 copies
of lysozyme mRNA per 10 ng of input RNA in the experimen-
tal samples. The reaction products were analyzed by melting
point determination (Fig. 2B). The melting temperature for
the lysozyme PCR product was approximately 83 C, and as
expected the products from all eight standard-curve reactions
had super imposable melting point curves. For comparison,
the melting proﬁle of a product from diﬀerent reaction, using
sPLA2 speciﬁc primers and intestinal cDNA template is also
shown (Tm = 87 C, Fig. 2B). The trace product generated in
the negative (no template) control at very high cycle number
(oﬀ the standard curve) is also shown (Fig. 2B) and likely rep-
resents primer dimers. The PCR products from representative
samples of this and all other reactions were also further con-
ﬁrmed by agarose gel analysis (for molecular weight determi-
nation) and by direct sequence analysis.
The relative abundance of antimicrobial peptide mRNA was
assessed by real-time PCR analysis (Fig. 2C). In the small
intestine, HD5 and HD6 mRNA are expressed at very high
concentrations of approximately 1–6 · 105 transcripts per
10 ng RNA. In the jejunum and duodenum, the level is pro-
gressively lower as compared to the ileum. HD5 and HD6
mRNA are coordinately expressed, with a ratio ranging from
approximately 3:1 to 6:1, respectively, in all three small intes-
tinal segments. This relative ratio is consistent with both
Northern blot data (Fig. 1), and prior studies using other
experimental techniques [25]. The esophagus, stomach, colon
and liver specimens had no detectable mRNA for either
HD5 or HD6. Since only single specimens of these tissues were
analyzed, we cannot exclude the possibility that other speci-
mens may show expression of these a-defensins. The bone
Fig. 2. Real-time PCR analysis of mRNA encoding antimicrobial peptides in gastrointestinal tissues and bone marrow. (A) Real-time ﬂuorescence
monitoring of PCR reactions using lysozyme primers and a DNA template consisting of serial dilutions of a lysozyme plasmid (standard 1–8). A
negative control (no template DNA) was also included. Inset, a standard curve generated from these data, plotting template concentration vs. PCR
cycle number of crossing points. (B) DNA melting point analysis of lysozyme PCR reaction products (standard 1–8 from panel A), as well as a PCR
reaction product of a separate reaction (sPLA2 product), and the negative control ampliﬁcation product from panel A. (C) Absolute quantiﬁcation of
mRNA encoding four Paneth cell antimicrobial peptides (HD5, HD6, sPLA2 (sPLA), lysozyme (Lys)), human neutrophil defensin 1–3 (HNP) and
GAPDH (GAPD) in eight diﬀerent gastrointestinal tissues and bone marrow. For all tissue samples, 5 lg of total RNA was reverse-transcribed into
cDNA, and an aliquot of the cDNA product (corresponding to 10 ng RNA) was used as a template for real-time PCR analysis with speciﬁc primers
(Table 1). The mRNA copy counts were determined from a standard curves using sequence speciﬁc plasmids (as in panel A) and are presented as
copies per 10 ng total RNA. Ileal samples (n = 5) were from non-diseased surgical samples of adjoining tissue resected from colon cancer. Error bars
represent standard deviations from the mean. Single specimens of commercially obtained RNA were analyzed for the other tissues.
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3 [3], also had no detectable HD5 or HD6 expression (Fig. 2C).HD5 and HD6 mRNA expression was detected in the pan-
creas, but at levels approximately 1000-fold lower than in the
Fig. 3. Localization of HD5 and lysozyme in duodenal mucosa. Mucosal tissue section was incubated with monoclonal 8C8 HD5 antibody and a
polyclonal lysozyme antiserum. Biotinylated anti-mouse IgG/Alexa 568 (red) streptavidin and Alexa 488 (green) conjugated anti-rabbit IgG were
used for immunodetection, respectively. The counterstain used was 4 0,6-Diamidino-2-phenylindole (DAPI). Boxed arrow denotes Brunner glands
staining exclusively with lysozyme, and line arrows show Paneth cells with colocalization of HD5 and lysozyme.
5348 J. Wehkamp et al. / FEBS Letters 580 (2006) 5344–5350ileum. Peptide expression in the pancreas, even at these lower
levels, was conﬁrmed by staining of discrete clusters of cells by
immunohistochemistry using HD5, HD6 and lysozyme anti-
sera (data not shown).
Another Paneth cell antimicrobial sPLA2 was expressed in
the jejunum and ileum at levels approximately 100-fold lower
than the a-defensins, with copy numbers of about 103–104
per 10 ng RNA (Fig. 2C). Expression of sPLA2 was observed
in the small intestine and colon, but not in the other tissues.
Lysozyme showed the highest levels of mRNA in the duode-
num, intermediate levels in the stomach, jejunum, ileum and
bone marrow, and lower levels in the colon, pancreas and liver
(Fig. 2C). Northern blot analysis also detected high lysozyme
mRNA levels in the duodenum (Fig. 1). In order to determine
the localization of lysozyme in the duodenum, immunoﬂuores-
cence was used. Accordingly, we detected lysozyme in two cell
types, Paneth cells and Brunner’s glands in the lamina propria
(Fig. 3). The localization in Brunner’s glands is consistent with
a previous immunohistochemical data [32]. In contrast to this
dual localization of lysozyme, HD5 was observed only in Pa-
neth cells, but not in the Brunner’s glands (Fig. 3).4. Discussion
Much experimental data supports the hypothesis that epithe-
lial-derived antimicrobial peptides and proteins contribute to
mucosal innate immunity [4,8,9,33]. Deﬁciencies in mucosal
defenses may result in infections [14,34–36] or various forms
of chronic inﬂammation [16,37]. The antimicrobials secreted
by Paneth cells are proposed to protect the small intestine from
food and water-borne pathogens, limit the numbers of
microbes colonizing the crypt and lumen, and help shape the
composition of the endogenous ﬂora [33]. This report system-
atically compares expression levels of Paneth cell antimicro-
bials in the major tissues of the normal gastrointestinal tract.
The quantities of antimicrobial peptides and proteins stored
and secreted by Paneth cells indicate that microbicidal concen-
trations can accumulate in the lumen of mice [38] and humans
[29]. For example, approximately 0.5 mg of HD5 is stored per
cm2 of ileal mucosa [29]. Consistent with this high peptide con-centration, we found the mRNA encoding Paneth cell a-defen-
sins HD5 and HD6 was constitutively very abundant in the
small intestine (Figs. 1 and 2). A recent investigation from
our group showed a close link between a-defensin mRNA lev-
els and peptide levels [16]. The gradient of a-defensin expres-
sion detected here for HD5 and HD6 is similar to that seen
for a-defensin cryptdin-4 in mice, when comparing duodenum,
jejunum and ileum [39]. In situ hybridization and immuno-
histochemical data have determined that HD5 and HD6 are
speciﬁcally expressed in Paneth cells in the small intestine
[24,29–31,40]. We also report here their expression in pancreas
tissue, but at levels roughly 1000-fold lower than those found
in the ileum. Although the colonic sample analyzed in this
study had no detectable HD5 or HD6 mRNA, we have found
these a-defensins previously in other normal and diseased
colonic specimens (unpublished observations). Similarly, the
other specimens, including the tissue specimens with no detect-
able a-defensin mRNA levels, might show variable levels of
expression under diﬀerent pathological, nutritional or physio-
logical conditions [23,41–44].
The other Paneth cell antimicrobials, lysozyme and sPLA2,
are expressed at high levels in the jejunum and ileum, but at
levels approximately 5-fold lower than the a-defensins. In the
duodenum, lysozyme is more highly expressed than the a-
defensins. At this location, lysozyme expression is observed
in both Paneth cells and Brunner’s glands located in the lamina
propria (Fig. 3). The mRNA of sPLA2 and lysozyme are ob-
served in bone marrow and other tissues, consistent with pre-
viously described expression in white cells and several
epithelial cell types of the GI tract [32,45–47].
Although a-defensins chronologically were identiﬁed ﬁrst in
phagocytic cells [3,48,49], gene sequence data suggests that
their epithelial counterparts may have existed before the pep-
tides of hematopoietic origin evolved [50]. This would suggest
that highly specialized mobile host defense cells such as neutro-
phils may have ‘‘borrowed’’ the genes encoding antimicrobial
peptides and other host defense-eﬀector molecules from an epi-
thelial cell defense armamentarium. It is interesting that the
levels of mRNA encoding the neutrophil a-defensins HNP1-
3 in the bone marrow are comparable to those encoding
HD5 and HD6 in the small intestinal mucosa.
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PCR provides a means to readily compare expression levels
of a speciﬁc gene in diﬀerent tissues or individuals. Alterna-
tively, it can also be used to compare mRNA expression levels
of diﬀerent genes in a single tissue. We normalized the real-
time RT-PCR data to the amount of total RNA, which both
simpliﬁes comparisons between diﬀerent RNA sources and be-
tween diﬀerent investigations. We concur with the recommen-
dation of Bustin and coworkers [26] that housekeeping gene
expression levels should also be measured and reported, but
not used to normalize the data. Normalization to housekeep-
ing gene mRNA levels can unnecessarily complicate compari-
sons, or worse yet, yield erroneous results since their levels are
not necessarily constant (in fact may vary by several orders of
magnitude) between diﬀerent tissues, with disease status, or in
response to pharmacological agents [26,51].
It should be noted that antimicrobial peptides and proteins
typically have antibiotic activity in the lg/ml range. Except in
conﬁned anatomical spaces where even trace quantities might
achieve this required concentration for activity, relatively high
expression levels of mRNA are required to generate microbi-
cidal concentrations of these peptides. Therefore, Northern
blot and in situ hybridization analyses have been valuable tech-
niques for screening tissues for antimicrobial expression, since
their relatively low sensitivity serves to focus attention on ana-
tomical sites of high expression. However, Northern blot and
in situ hybridization data are much less amenable to precise
quantitation than real-time RT-PCR. Non-quantitative RT-
PCR analysis is very sensitive, and, because of this sensitivity,
may detect mRNA expression at levels lower than suﬃcient
to generate biologically signiﬁcant peptide expression. By con-
trast, the real-time quantitative RT-PCR analysis used in this
study provides an absolute number of mRNA transcripts,
expressed as copies per quantity of total RNA.
In summary, quantitative real-time RT-PCR is a powerful
technique to assess mRNA expression. Using this methodol-
ogy, we determined that mRNA encoding the Paneth cell a-
defensins HD5 and HD6 are highly abundant in the small
intestine. The mRNA levels encoding these a-defensins in the
small intestine are comparable to the levels we detected for
the neutrophil a-defensins HNP1-3 in bone marrow. The other
Paneth cell antimicrobials, lysozyme and sPLA2, have less tis-
sue speciﬁcity than HD5 and HD6. In the duodenum, high-le-
vel lysozyme expression is attributed to the expression of the
antimicrobial in Brunner’s glands, in addition to that found
in Paneth cells. Quantitative real-time RT-PCR has gained
general acceptance as a method to facilitate investigations
requiring precise quantitation of mRNA, and our analysis of
normal of expression levels will be useful for comparisons with
disease tissues, such as Crohn’s disease [16]. We anticipate that
our methodological approach using external standards and
normalization to total RNA concentrations will provide a use-
ful means of comparing antimicrobial peptide expression data
between investigations in separate laboratories.
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